TriangleEndocrine Therapy (NCT05919108)
Endocrine Therapy trial for Anatomic Stage I Breast Cancer (NCT05919108). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with untreated stage I–III, estrogen-receptor-positive invasive lobular breast cancer carrying an activating HER2 mutation. HER2 amplification is excluded; tumors must measure at least 1.5 centimeters.
The idea: neratinib blocks HER2 growth signaling. Patients are randomized to endocrine therapy alone or with neratinib for four weeks. Both groups then receive endocrine therapy plus daily oral neratinib for twenty weeks, followed by surgery. Research biopsies and blood tests assess treatment effects.
This phase 2 study plans 30 patients. Laura Kennedy leads at Vanderbilt; sites in Nashville and Dallas are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.